Open an account

Adia Nutrition

ADIA · OTC

$0.12−$0.01 (−7.69%)TodayMarket closed ·
No price history for this range.

About ADIA

Adia Nutrition, Inc. is engaged in the creation of probiotics. The company is headquartered in Winter Park, Florida. The company went IPO on 2004-03-23. The Company’s divisions include supplement division and medical division. The supplement division provides organic supplements. The medical division establishes clinics that specialize in stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Adia Med of Winter Park, LLC, its subsidiary, operates clinic to perform treatments, and Adia Labs, LLC, its subsidiary, procures and sells the products relating to these procedures. Adia Med is conducting a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) and exosome treatments, like AdiaVita from Adia Labs LLC, with at least 100 million stem cells and three trillion exosomes per unit. These therapies address chronic inflammation, autoimmune disorders, and orthopedic issues. The firm has approximately 18% equity position in Cement Factory, LLC.

Employees
0
Headquarters
Winter Park, Florida
Listed
Mar 23, 2004
Sector
Consumer Staples
Industry
Personal Care Products
Website
adianutrition.com

ADIA key statistics

Market cap
11.33M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
24.30K
Volume
19.50K
Open price
$0.1205
High today
$0.1205
Low today
$0.12
52 Week high
$0.2777
52 Week low
$0.025

Adia Nutrition (ADIA) at a glance

Adia Nutrition (ADIA) last traded at $0.12, with a market cap of 11.33M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.12 and $0.1205. The current price is 0.0% above the day's low and 0.4% below its high.

Volume so far is 19.50K shares, in line with the average of 24.30K shares a day.

Over the past year Adia Nutrition has ranged from $0.025 to $0.2777, and now sits 38% of the way up that range.

ADIA news

  • Press releaseNewsfile

    Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash

  • Press releaseNewsfile

    Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position

  • Press releaseNewsfile

    Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million

  • Press releaseNewsfile

    Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line

  • Press releaseNewsfile

    Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products

  • Press releaseNewsfile

    Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment

  • Press releaseNewsfile

    Nasdaq Shareholder Requirements Just Verified By Adia Med

  • Press releaseNewsfile

    From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team

Similar companies

Companies in the same industry as Adia Nutrition

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.